Study KBP-2020-CPHG Documenting New Cases of Primary Lung Cancer (PLC) Diagnosed in Respiratory Medicine Departments and Lung Cancer Units at General Hospitals From January 1st to December 31st 2020

NCT04402099 | Unknown DMC

• 1 other identifier: 2019-A00943-54
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

Twenty years after KBP-2000-CPHG study and ten years after KBP-2010-CPHG study, the CPHG proposes to conduct a new epidemiological study on primary PLC in order to evaluate and analyze the changes that have occurred over the last decade. Primary endpoint: Estimate 1-year- and 5-year-mortality rates in patients with PLC. Secondary endpoints:

• Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020
• Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies
• Estimate prognostic factors
• Compare patient and tumor characteristics to those observed for KBP-2010-CPHG and KBP-2000-CPHG studies
• Compare observed survival rates to those reported for KBP-2000-CPHG and KBP-2010-CPHG studies

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (2)

• Estimate 1-year mortality rates in patients with PLC.

  Global survival at 1 year

  1 year

• Estimate 5-year mortality rates in patients with PLC.

  Global survival at 5 years

  5 years

Secondary Outcomes (2)

• Describe PLC patient population managed by pulmonologists at French General Hospitals in 2020

  1 year

• Describe PLC diagnostic and therapeutic management by pulmonologists at French General Hospitals in 2020 and compare them to KBP-2000-CPHG and KBP-2010-CPHG studies

  1 year

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Primary Lung Cancer histologically proven between January 1st and December 31st, 2020

You may qualify if:

• Age ≥ 18 years
• Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020\*
• Follow-up by a lung specialist at a General Hospital
• Oral informed consent \* date of collected sample

You may not qualify if:

• Age \< 18 years
• Secondary lung cancer
• Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery
• Previous enrolment in the study
• Freedom deprived patient following a legal or administrative decision
• Patient unable to give his(her) consent

Sponsors & Collaborators

• Collège des Pneumologues des Hôpitaux Généraux: lead

Study Sites (1)

Collège des Pneumologues des Hôpitaux Généraux (CPHG) (General Hospital Pulmonologists College)

Paris, 75006, France

RECRUITING

Related Publications (1)

• Debieuvre D, Falchero L, Molinier O, Couraud S, Cortot A, Meyer N, Asselain B, Auvray E, Templement-Grangerat D, Bizieux A, Tredaniel J, Schneider S, Auliac JB, Bylicki O, Letierce A, Morel H. Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020. NEJM Evid. 2025 Jul;4(7):EVIDoa2400443. doi: 10.1056/EVIDoa2400443. Epub 2025 Jun 24.

  PMID: 40552964 DERIVED

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 27, 2020
• First Posted: May 26, 2020
• Study Start: January 1, 2020
• Primary Completion: January 1, 2026
• Study Completion: January 1, 2026
• Last Updated: June 5, 2020

Record last verified: 2020-06

Locations

FR (1)